Day: February 28, 2025

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Written by Customer Service on February 28, 2025. Posted in Earnings Releases And Operating Results.

— Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study — — Completed enrollment of the double-blinded portion of the Phase 3 SYNCHRONY Real-World Study evaluating EFX in patients with either MASLD or MASH — — Presented New Analyses of Week 96 Phase 2b HARMONY in Patients with Pre-Cirrhotic (F2-F3) MASH at the 75th Annual AASLD The Liver Meeting® 2024 — SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today reported fourth quarter and full year financial results for the period...

Boralex reports net earnings of $74 million for fiscal 2024 and continues construction of its large-scale projects in Québec, Ontario and the United Kingdom

Written by Customer Service on February 28, 2025. Posted in Earnings Releases And Operating Results.

MONTREAL, Feb. 28, 2025 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the three-month period and year ended December 31, 2024. HighlightsFinancial resultsEBITDA(A)1, operating income and net earnings under pressure in Q4-2024 owing to adverse wind and hydropower conditionsProduction 16% (11% on a Combined1 basis)2 lower than in Q4-2023 and 16% (12%) below anticipated production1, due primarily to the adverse climate conditions. For fiscal 2024 overall, production was 5% (2%) lower than in 2023 and 10% (8%) below anticipated production. EBITDA(A) of $169 million ($191 million) for Q4-2024, down $33 million ($38 million) from Q4-2023. For fiscal 2024, EBITDA(A) was $581 million ($670 million), up $3 million (down $5 million) from 2023. The decrease in production...

Opthea Reports Half Year Results and Business Updates

Written by Customer Service on February 28, 2025. Posted in Earnings Releases And Operating Results.

Cash and cash equivalents of $131.9M as of December 31, 2024 Cash runway extends through anticipated topline data readouts of COAST (early 2Q CY25) and ShORe (mid-CY25) MELBOURNE, Australia and PRINCETON, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced financial results for the six months ended December 31, 2024, and highlighted recent corporate and clinical updates. “Opthea is making significant progress on its mission to deliver superior vision to patients with wet AMD enabling them to live fuller and healthier lives,” said Frederic Guerard, PharmD, Chief Executive Officer of...

Fairfax Announces Intention to Redeem Cumulative Preferred Shares, Series E, F & M

Written by Customer Service on February 28, 2025. Posted in Dividend Reports And Estimates.

TORONTO, Feb. 28, 2025 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) today announced its intention to redeem (i) all of its 5,440,132 outstanding Cumulative 5-Year Rate Reset Preferred Shares, Series E (the “Series E Shares”), (ii) all of its 2,099,046 outstanding Cumulative Floating Rate Preferred Shares, Series F (the “Series F Shares”), and (iii) all of its 9,200,000 outstanding Cumulative 5-Year Rate Reset Preferred Shares, Series M (the “Series M Shares” and, collectively with the Series E Shares and the Series F Shares, the “Preferred Shares”) on March 31, 2025 (the “Redemption Date”) at a redemption price equal to C$25.00 per share, for an aggregate total amount of approximately C$420.5 million, together with all accrued and unpaid dividends up to but excluding the Redemption Date...

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Written by Customer Service on February 28, 2025. Posted in Public Companies.

New website launched in honor of Rare Disease Day, Feb. 28, 2025 Awareness campaign includes educational resources and testing information for individuals with suspected NPC. CELEBRATION, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies to people living with rare disease, today announced, on Rare Disease Day, the launch of a new disease state awareness campaign, ’Learn NPC, Read Between the Signs,’ to highlight the need for early recognition and diagnosis due to the heterogeneity of symptoms related to Niemann-Pick disease type C (NPC). NPC is an ultra-rare, progressive, and neurodegenerative lysosomal storage disorder with varying age of onset and symptom presentation, often making the pathway to diagnosis difficult.“We...

AGM Group Holdings Inc. Announces Strategic Partnership with HashBeaver to Drive Blockchain and AI Innovation

Written by Customer Service on February 28, 2025. Posted in Public Companies.

Beijing, Feb. 28, 2025 (GLOBE NEWSWIRE) — AGM Group Holdings Inc. (“AGM Holdings” or the “Company”) (NASDAQ: AGMH), an integrated technology company specializing in the assembling and sales of high-performance hardware and computing equipment, announced today a strategic partnership agreement (the “Agreement”) with HashBeaver, a cloud mining platform in the digital currency financial sector. This collaboration aims to join AGM Holdings’ mining resources in Canada alongside HashBeaver’s expertise in computing power services to advance innovations in Bitcoin mining and artificial intelligence (“AI”) services. The partnership marks a pivotal step in AGM Holdings’ strategy for sustainable growth and technological leadership. By integrating AGM Holdings’ robust infrastructure with HashBeaver’s innovative cloud mining solutions, the...

Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

Written by Customer Service on February 28, 2025. Posted in Public Companies.

DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company’s website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until March 10, 2026. About BioventusBioventus...

Emerging Markets Report: Crystal Balls, Clarity & Confidence

Written by Customer Service on February 28, 2025. Posted in Public Companies.

An Emerging Markets Sponsored Commentary ORLANDO, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) — In a recent edition of the Emerging Markets Report we brought to your attention a compelling story in the phosphate industry. We outlined the correlation between phosphate and the Electric Vehicle (EV) industry and how if one believed in the future of EVs, that phosphate deals were a natural extension to explore. You can read that essay on First Phosphate Corp. (CSE: PHOS) (OTCQB: FRSPF) (FSE: KD0) at this link. Just a few days ago, First Phosphate dropped a nuts and bolts press release about their progress. There are no glaring headlines, no bold claims, no saucy hyperbole in flourished CEO quotes. Instead, there is a significant update not often seen in public company parlance that gives you a real understanding of where the Company is in...

2025 Financial Calendar

Written by Customer Service on February 28, 2025. Posted in Public Companies.

28. February 2025 News Release: The board has decided that Pharma Equity Group A/S will in future only submit half-yearly financial reports. This means changes to the previously announced financial calendar for 2025. The current financial calendar for 2025 will look like this: Pharma Equity Group2025 Financial Calendar March 4 Deadline for shareholder proposals – Annual General meeting March 20 Annual Report 2024 April 16 Annual General Meeting August 14 Interim Report – for the six-month period ended June 30, 2025 Contact person – Investor Relations On the Company’s website www.pharmaequitygroup.com further information and all published announcements can be found. Inquiries regarding relations with investors and the stock market can be directed to: Thomas Kaas Selsø, CEO, Phone: +45 4022 2114...

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on February 28, 2025. Posted in Earnings Releases And Operating Results.

Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growthSYFOVRE® (pegcetacoplan injection) full year 2024 net product revenue of $611.9 million EMPAVELI® (pegcetacoplan) full year 2024 net product revenue of $98.1 millionSubmitted a supplemental new drug application (sNDA) for approval of EMPAVELI for C3G and primary IC-MPGN; U.S. launch anticipated in 2H 2025, if approved On track to initiate two Phase 3 trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025 Cash and cash equivalents of $411.3 million as of December 31, 2024; projected revenues and cash expected to be sufficient to fund operations to profitability Management to host conference call today at 8:30 a.m. ETWALTHAM, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc....

Day: February 28, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals